185 related articles for article (PubMed ID: 21191555)
21. Treatment of invasive fungal infections in high-risk haematological patients: what have we learnt in the past 10 years?
Vallejo C; Vázquez L; Cabrera Martín JR; Carreras E; García Rodríguez J; Ruiz Camps I; Fortún J; Mensa J; Barberán J
Rev Esp Quimioter; 2013 Dec; 26(4):378-86. PubMed ID: 24399355
[TBL] [Abstract][Full Text] [Related]
22. Antifungal prophylaxis with itraconazole oral solution in neutropenic patients.
Kibbler CC
Mycoses; 1999; 42 Suppl 2():121-4. PubMed ID: 10865918
[TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapy approaches to antifungal prophylaxis.
Ng TB; Cheung RC; Ye Xj; Fang EF; Chan YS; Pan WL; Dan XL; Yin CM; Lam SK; Lin P; Ngai PH; Xia LX; Liu F; Ye XY; Wang HX; Wong JH
Expert Opin Pharmacother; 2012 Aug; 13(12):1695-705. PubMed ID: 22716311
[TBL] [Abstract][Full Text] [Related]
24. How to improve the design of trials of antifungal prophylaxis among neutropenic adults with acute leukemia.
Menichetti F
Clin Infect Dis; 2004 Oct; 39 Suppl 4():S181-4. PubMed ID: 15546115
[TBL] [Abstract][Full Text] [Related]
25. Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies.
Murali S; Langston A
Transpl Infect Dis; 2009 Dec; 11(6):480-90. PubMed ID: 19725908
[TBL] [Abstract][Full Text] [Related]
26. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
27. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
28. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
[TBL] [Abstract][Full Text] [Related]
29. [Antimicrobial prophylaxis and therapy in neutropenia].
Link H
Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
[TBL] [Abstract][Full Text] [Related]
30. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Glasmacher A; Prentice AG
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
[TBL] [Abstract][Full Text] [Related]
31. [Prevention of fungal infections in children and adolescents with cancer].
Groll AH; Ritter J; Müller FM
Klin Padiatr; 2001 Sep; 213 Suppl 1():A50-68. PubMed ID: 11577364
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic SCT in patients with a history of invasive fungal infection.
Zhang P; Song A; Wang Z; Feng S; Qiu L; Han M
Bone Marrow Transplant; 2009 Apr; 43(7):533-7. PubMed ID: 19104496
[TBL] [Abstract][Full Text] [Related]
33. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
34. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients?
Salavert M
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S149-53. PubMed ID: 19013340
[TBL] [Abstract][Full Text] [Related]
35. [Recommendations of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the prevention of invasive fungal infection due to filamentous fungi].
Ruiz-Camps I; Aguado JM; Almirante B; Bouza E; Ferrer Barbera C; Len O; López-Cerero L; Rodríguez-Tudela JL; Ruiz M; Solé A; Vallejo C; Vázquez L; Zaragoza R; Cuenca-Estrella M;
Enferm Infecc Microbiol Clin; 2010 Mar; 28(3):172.e1-172.e21. PubMed ID: 20202721
[TBL] [Abstract][Full Text] [Related]
36. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies.
Leather HL; Wingard JR
Blood Rev; 2006 Sep; 20(5):267-87. PubMed ID: 16781028
[TBL] [Abstract][Full Text] [Related]
37. Antifungal treatment in patients with cancer.
Viscoli C; Castagnola E; Machetti M
J Intern Med Suppl; 1997; 740():89-94. PubMed ID: 9350188
[TBL] [Abstract][Full Text] [Related]
38. [Invasive fungal infections in patients with blood disorders].
López F; Jarque I; Martín G; Sanz GF; Palau J; Martínez J; de la Rubia J; Larrea L; Arnao M; Solves P; Cervera J; Martínez ML; Pemán J; Gobernado M; Sanz MA
Med Clin (Barc); 1998 Mar; 110(11):401-5. PubMed ID: 9608494
[TBL] [Abstract][Full Text] [Related]
39. Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use.
Sugar AM
Arch Intern Med; 1990 Nov; 150(11):2258-64. PubMed ID: 2241435
[TBL] [Abstract][Full Text] [Related]
40. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
McCoy D; Depestel DD; Carver PL
Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
